The use of positron emission tomography (pet) in the diagnosis of neurodegenerative diseases of the elderly
DOI:
https://doi.org/10.15448/2357-9641.2017.1.28174Abstract
---Downloads
References
Sokoloff L, Reivich M, Kennedy C, et al. The (14 C)-
deoxyglucose method for measurement of local cerebral
glucose utilization: theory, procedure and normal values in
the conscious and anesthetized albino rat. J Neurochem.
;28:897-916.
Pawlik G, Heiss WD. Positron emission tomography and
neuropsychological function. In: Bigler ED, Yeo RA,
Turkheimer E (eds). Neuropsychological function and brain
imaging. New York: Plenum Publ. Corp.; 1989. p. 65-138.
Heiss WD, Zimmermann-Meinzingen S. PET imaging in
the differential diagnosis of vascular dementia. J Neurol Sci.
;322(1-2):268-73.
Mosconi L. Glucose metabolism in normal aging and
Alzheimer’s disease: Methodological and physiological
considerations for PET studies. Clin Transl Imaging.
;1(4):217-33.
Salmon E. Functional brain imaging applications to
differential diagnosis in the dementias. Curr Opin Neurol.
;15(4):439-44.
Mosconi L, et al. FDG-PET changes in brain glucose
metabolism from normal cognition to pathologically
verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging.
;36:811-22.
Herholz K, et al. Discrimination between Alzheimer
Dementia and Controls by Automated Analysis of
Multicenter FDG PET. Neuroimage. 2002;17(1):302-16.
Silverman DH, Small GW, Chang CY, et al. Positron emission
tomography in evaluation of dementia: Regional brain
metabolism and long-term outcome. JAMA. 2001;286(17):
-7.
De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal
formation glucose metabolism and volume losses in MCI
and AD. Neurobiology of aging. 2001;22(4):529-39.
Gauthier S, et al. Mild cognitive impairment. Lancet.
;367:1262-70.
Jeong Y, et al. 18F-FDG PET Findings in Frontotemporal
Dementia: An SPM Analysis of 29 Patients. J Nucl Med.
;46:233-9.
Foster NL, et al. FDG-PET improves accuracy in
distinguishing frontotemporal dementia and Alzheimer’s
disease. Brain. 2007;130:2616-35.
Spehl TS, Hellwig S, Amtage F, et al. Syndrome-Specific
Patterns of Regional Cerebral Glucose Metabolism in
Posterior Cortical Atrophy in Comparison to Dementia
with Lewy Bodies and Alzheimer’s Disease-A [F-18]-Fdg
Pet Study. J Neuroimaging. 2015;25(2):281-8.
Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral
glucose metabolic features of Parkinson disease and
incident dementia: longitudinal study. J Nucl Med. 2011;
(6):848-55.
Diehl-Schmid J, Grimmer T, Drzezga A, et al. Decline of
cerebral glucose metabolism in frontotemporal dementia:
a longitudinal 18F-FDG-PET-study. Neurobiol aging.
;28(1):42-50.
Mosconi L, et al. Multicenter standardized 18F-FDG
PET diagnosis of mild cognitive impairment, Alzheimer’s
Disease, and other dementias. J Nucl Med. 2008;49(3):
-8.
Gomperts SN, Rentz DM, Moran E, et al. Imaging
amyloid deposition in Lewy body diseases. Neurology.
;71(12):903-10.
Antonini A, et al. Differential diagnosis of parkinsonism
with FDG and PET. Mov Disord. 1998;13:268-74.
Eckert T, et al. FDG PET in the differential diagnosis of
parkinsonian disorders. Neuroimage. 2005;26:912-21.
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The submission of originals to PAJAR implies the transfer by the authors of the right for publication. Authors retain copyright and grant the journal right of first publication. If the authors wish to include the same data into another publication, they must cite PAJAR as the site of original publication.
Creative Commons License
Except where otherwise specified, material published in this journal is licensed under a Creative Commons Attribution 4.0 International license, which allows unrestricted use, distribution and reproduction in any medium, provided the original publication is correctly cited.
